Blinatumomab (trade name Blincyto, previously known as AMG103 and MT103) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia...Wikipedia
Manufacturer's Website: Blincyto Average retail cost: $3,726/dose
Search Terms: Blincyto, blinatumomab, Philadelphia chromosome-negative, lymphoblastic leukemia